Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 5, 2007, Pages 555-559

  Micol, Romain ^a,h   Lortholary, Olivier ^a,b   Sar, Borann ^c   Laureillard, Didier ^d   Ngeth, ChanChhaya ^e   Dousset, Jean Philippe ^f   Chanroeun, Hak ^f   Ferradini, Laurent ^g   Guerin, Philippe Jean ^g   Dromer, Françoise ^a   Fontanet, Arnaud ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e Preah Bat Norodom Sihanouk Hospital   (Cambodia)

^f Hopital Calmette   (Cambodia)

^g EPICENTRE   (France)

^h Emerging Diseases Epidemiology Unit   (France)

Author keywords

AIDS; Cambodia; Cryptococcal antigenemia; Cryptococcosis; Cryptococcus neoformans; HIV; Screening

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; FLUCONAZOLE; FLUCYTOSINE;

ADULT; ARTICLE; BODY MASS; CAMBODIA; CD4+ T LYMPHOCYTE; CONSULTATION; CONTROLLED STUDY; CRYPTOCOCCAL ANTIGENEMIA; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX RATIO; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, FUNGAL; BIOLOGICAL MARKERS; BODY MASS INDEX; CAMBODIA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEADACHE; HIV; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 34548079199     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31811ed32c     Document Type: Article

References (18)

1. Chariyalertsak S, Sirisanthana T, Saengwonloey O, et al. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-1998: regional variation and temporal trends. Clin Infect Dis. 2001;32:955-962.
2. Amornkul PN, Hu DJ, Tansuphasawadikul S, et al. Human immunodeficiency virus type 1 subtype and other factors associated with extra-pulmonary cryptococcosis among patients in Thailand with AIDS. AIDS Res Hum Retroviruses. 2003;19:85-90.
3. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis. 2002;34:277-284.
4. Chhin S, Rozycki G, Pugatch D, et al. Aetiology of meningitis in HIV-infected patients in a referral hospital in Phnom Penh, Cambodia. Int J STD AIDS. 2004;15:48-50.
5. Pichith K, Chanroeun H, Bunna P, et al. Clinical aspects of AIDS at the Calmette Hospital in Phnom Penh, Kingdom of Cambodia. A report on 356 patients hospitalized in the Medicine "B" Department of the Calmette Hospital. Sante. 2001;11:17-23.
6. Temstet A, Roux P, Poirot JL, et al. Evaluation of a monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies. J Clin Microbiol. 1992;30:2544-2550.
7. Dromer F, Gueho E, Ronin O, et al. Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol. 1993;31:359-363.
8. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19.
9. Dromer F, Mathoulin-Pelissier S, Launay O, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4:e21.
10. Dromer F, Mathoulin S, Dupont B, et al. Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group. Clin Infect Dis. 1996;23:91-96.
11. Dromer F, Mathoulin-Pelissier S, Fontanet A, et al. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre-and post-HAART eras. AIDS. 2004;18:555-562.
12. Sorvillo F, Beall G, Turner PA, et al. Incidence and factors associated with extrapulmonary cryptococcosis among persons with HIV infection in Los Angeles County. AIDS. 1997;11:673-679.
13. Hajjeh RA, Conn LA, Stephens DS, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis. 1999;179:449-454.
14. Kuroki M, Phichaichumpon C, Yasuoka A, et al. Environmental isolation of Cryptococcus neoformans from an endemic region of HIV-associated cryptococcosis in Thailand. Yeast. 2004;21:809-812.
15. Feldmesser M, Harris C, Reichberg S, et al. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis. 1996;23:827-830.
16. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Disease Society of America. Clin Infect Dis. 2000;30:710-718.
17. Lortholary O, Fontanet A, Memain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005;19:1043-1049.
18. Desmet P, Kayembe KD, De Vroey C. The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS. 1989;3:77-78.